The identification of patients with FH allows the initiation of lipid-lowering treatment consisting mainly of statins in combination or not with other drugs, such as ezetimibe or PCSK9 inhibitors (PCSK9i). This evidence concerns the gene PCSK9 and familial hyperaldosteronism.